Funding
We are thankful to our funding agencies for their support:
Baden Württemberg Stiftung
REsolvInG ImmuNITy to targEt Brain Tumors (RE-IGNITE). 2020 - 2023
Deutsche Krebshilfe
A MultIceNTer PhasE I RNA VaCcine Trial to Exploit NeoePitope-Specific T Cells for the Treatment of H3K27M-Mutated Gliomas – (INTERCEPT H3). 2019 - 2024
Microglial immune surveillance of oncogenic IDH (CONVINCE-IDH). 2023 - 2026
Deutsches Konsortium für Translationale Krebsforschung
TCR Proof of Concept in cooperation with NCT (TCR-POC)
AMPLIFYing NEOepitope-specific VACcine Responses in progressive diffuse glioma – a randomized, open label, 3 arm multicenter Phase I trial (AMPLIFY-NEOVAC, NOA-21)
CAR2Brain_Immune Response CAR-NK Immunotherapy in Glioblastoma_DKTK Joint Funding "UPGRADE". 2020 - 2024
Insights into mechanisms of T cell response and resistance in post-treatment multicellular AMPLIFY NEOVAC glioma organoids (AMI2GO) 2021 - 2024
Intraventricular TCR therapy for glioblastoma (INVENT4GB) 2023 - 2026
Translational research program using longitudinal biosamples from enrolled patients during
intrathecal immunotherapy within the multicenter investigator-inititated IT-PD1/NOA-26 clinical
study (TRUST) 2023-2026
Monitoring the immune modulating effects of combinatorial targeted and immune checkpoint inhibitor treatment (MIMETIC) 2023-2026
PREDICT 2023-2026
Deutsche Forschungsgemeinschaft - CRC 1366
© dkfz.de
Vascular control of tumor immunity in the CNS. CRC1366. 2023 - 2026
Deutsche Forschungsgemeinschaft - CRC UNITE 1389
Understanding and targeting resistance in glioblastoma. CRC UNITE 1389. 2023 - 2026
Deutsche Forschungsgemeinschaft - RTG 2099
© dkfz.de
Hallmarks of Skin Cancer, Tumor Microenvironment and Melanoma Immunity, Response and Resistance to Checkpoint Blockade in melanoma brain metastases. CRC RTG2099. 2019 - 2024
Deutsche Forschungsgemeinschaft - GRK 2727/1
© dkfz.de
InCheck „Innate Immune Checkpoints in Cancer and Tissue Damage"
DKFZ-MOST
Characterizing and targeting the major histocompatibility complex class II-dependent immunome in brain tumors (COMBAT)- Ca214 2023 - 2026
Hertie Stiftung
Hertie Academy of clinical neuroscience als Kristallisationspunkt für ein Hertie Network of Excellence in clinical neuriscience. 2019 - 2026